Sanofi Pursues Ocular Therapeutix Acquisition Ahead of Pivotal Trial Results
Sanofi has submitted a revised acquisition bid for Ocular Therapeutix ahead of pivotal Phase 3 trial results for AXPAXLI, a sustained-release treatment for wet AMD. The deal could position Sanofi to re-enter the ophthalmology market it previously abandoned. The acquisition would give Sanofi access to innovative hydrogel delivery technology with potential applications beyond eye disease.
French pharmaceutical giant Sanofi has reportedly returned to the negotiating table with a significantly "sweetened" revised bid for Ocular Therapeutix. The updated offer comes as Ocular Therapeutix is scheduled to release topline results from its landmark Phase 3 SOL-1 trial, with the potential deal hinging almost entirely on the success of AXPAXLI, Ocular's flagship sustained-release hydrogel implant for wet age-related macular degeneration.
The relationship between Sanofi and Ocular Therapeutix has intensified rapidly over the last six months. In September 2025, Sanofi made an initial offer to acquire the company at $16 per share, a deal valued at approximately $2.3 billion, which Ocular's board rejected as "opportunistic." As the February 2026 deadline for the SOL-1 trial results approached, reports indicated that Sanofi had authorized a higher offer, rumored to be in the range of $22 to $28 per share.
The urgency behind Sanofi's persistence is tied directly to the design of the SOL-1 trial, which is a superiority trial designed to prove that AXPAXLI—a tyrosine kinase inhibitor delivered via Ocular's proprietary ELUTYX hydrogel platform—is more effective at maintaining visual acuity with a significantly lower treatment burden than the current standard of care. If the data meets its primary endpoints, it would validate a treatment regimen that requires dosing only once every six to nine months, a radical improvement over the monthly or bimonthly injections required by current market leaders.
If the acquisition is finalized following positive trial results, the immediate winner would be the shareholders of Ocular Therapeutix. For Sanofi, the acquisition would represent a strategic triumph as the company has been under pressure to diversify its revenue stream ahead of the 2031 "patent cliff" for its blockbuster drug Dupixent. By acquiring the ELUTYX platform, Sanofi would not only gain AXPAXLI but also a versatile delivery system that could be used for other biologics in its immunology and inflammation pipelines.
A successful AXPAXLI launch under Sanofi's massive global commercial infrastructure could rapidly erode the market for Eylea HD and Roche's Vabysmo. This move by Sanofi is also being viewed through the lens of historical redemption, as in 2013, Sanofi famously returned the rights to early versions of aflibercept to Regeneron, effectively walking away from what became a $9 billion franchise.